Papaporfyriou, A.; Bartziokas, K.; Apessos, I.; Mueller, J.; Leivaditis, V.; Koletsis, E.; Grapatsas, K.
Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review. Curr. Oncol. 2024, 31, 6289-6299.
https://doi.org/10.3390/curroncol31100469
AMA Style
Papaporfyriou A, Bartziokas K, Apessos I, Mueller J, Leivaditis V, Koletsis E, Grapatsas K.
Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review. Current Oncology. 2024; 31(10):6289-6299.
https://doi.org/10.3390/curroncol31100469
Chicago/Turabian Style
Papaporfyriou, Anastasia, Konstantinos Bartziokas, Ioulianos Apessos, Jan Mueller, Vasileios Leivaditis, Efstratios Koletsis, and Konstantinos Grapatsas.
2024. "Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review" Current Oncology 31, no. 10: 6289-6299.
https://doi.org/10.3390/curroncol31100469
APA Style
Papaporfyriou, A., Bartziokas, K., Apessos, I., Mueller, J., Leivaditis, V., Koletsis, E., & Grapatsas, K.
(2024). Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review. Current Oncology, 31(10), 6289-6299.
https://doi.org/10.3390/curroncol31100469
